Centene Corporation
CNC
$64.58
-3.67%
Centene Corporation is a managed care organization that provides government-sponsored healthcare plans, including Medicaid, Medicare, and individual health insurance exchanges, serving approximately 20 million medical members as of December 2025. As one of the largest Medicaid managed care providers in the United States, Centene holds a dominant position in the government-sponsored healthcare market, with a diversified portfolio across commercial and Medicare segments. The current investor narrative centers on the company's strategic pivot toward profitability following a period of membership losses in its Affordable Care Act (ACA) exchange business, which has led to cost-cutting measures such as voluntary staff buyouts. Additionally, recent positive developments, including a larger-than-expected Medicare Advantage payment increase from CMS, have boosted sector sentiment and raised expectations for improved revenue visibility and margin recovery.…
CNC
Centene Corporation
$64.58
Related headlines
Investment Opinion: Should I buy CNC Today?
Rating: Buy. Centene offers a compelling risk/reward with a forward PE of 12.62x and a PS ratio of 0.10x, which are attractive relative to its growth potential. The analyst consensus is 'buy' with an average target price of $71.67, implying 6.9% upside from the current price of $67.04. The company's revenue growth of 7.13% YoY and strong free cash flow of $6.35 billion support the thesis that the turnaround is on track. The main risks are membership losses in ACA and high leverage, but the positive sector tailwinds and cost-cutting measures provide a buffer. This Buy rating would be downgraded if revenue growth decelerates below 5% or if the forward PE expands above 15x without corresponding earnings growth.
Sign up to view all
CNC 12-Month Price Forecast
The AI assessment leans bullish, driven by the company's strong revenue growth, attractive valuation, and robust cash flow. However, the medium confidence reflects the uncertainty around ACA membership stabilization and the high leverage. The stock's recent outperformance suggests momentum, but the forward PE implies high expectations. If Centene delivers on its EPS projections and maintains revenue growth, the stock could reach the high target. Conversely, any negative surprises could trigger a correction. The stance would be upgraded to high confidence if the company reports two consecutive quarters of EPS beats and membership growth.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Centene Corporation's 12-month outlook, with a consensus price target around $71.67 and implied upside of +11.0% versus the current price.
Average Target
$71.67
0 analysts
Implied Upside
+11.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$56 - $85
Analyst target range
The target price range spans from a low of $56.00 to a high of $85.00, with the high target suggesting a potential upside of 26.8% from current levels, likely reflecting expectations of continued margin expansion and membership stabilization. The low target of $56.00 implies a downside of -16.5%, which could materialize if the company faces further membership losses or regulatory headwinds. Recent institutional ratings have been largely stable, with firms like Wells Fargo, RBC Capital, and JP Morgan maintaining their existing ratings, while no major upgrades or downgrades have occurred in the past few months, indicating a steady outlook.
Drowning in data?
Find the real signal!
Bulls vs Bears: CNC Investment Factors
Centene presents a compelling turnaround story with strong revenue growth, robust free cash flow, and a low forward valuation. However, the company faces significant challenges, including negative trailing earnings, ACA membership losses, and high leverage. The bull case currently has stronger evidence, supported by the exceptional stock performance and positive sector tailwinds, but the bear case highlights the fragility of the recovery. The most critical tension is whether Centene can sustain its earnings recovery and stabilize membership, as the forward PE of 12.62x assumes a dramatic EPS rebound. If the company delivers on its EPS projections, the stock has further upside; if not, the downside to $56 or lower is real.
Bullish
- Exceptional 1-Year Price Surge: CNC's stock has rallied +134.0% over the past year, vastly outperforming the S&P 500's +18.65% gain. This demonstrates strong investor conviction in the company's turnaround story and improving fundamentals.
- Robust Revenue Growth: Q1 2026 revenue grew 7.13% YoY to $49.94 billion, driven by the Medicaid segment ($39.21B) and Commercial segment ($9.56B). This indicates continued demand for government-sponsored healthcare plans.
- Attractive Forward Valuation: With a forward PE of 12.62x and a price-to-sales ratio of 0.10x, the stock appears undervalued relative to its growth prospects. Analysts project EPS of $9.06 for the next fiscal year, implying a significant earnings recovery.
- Strong Free Cash Flow Generation: Centene generated $6.35 billion in trailing twelve-month free cash flow, providing ample liquidity for debt reduction, share buybacks, or strategic investments. This cash flow supports the company's financial flexibility.
Bearish
- Negative Trailing Earnings: Centene's trailing twelve-month EPS is -$0.33, reflecting recent losses driven by ACA membership declines and restructuring charges. The negative net margin of -3.43% indicates profitability challenges.
- Membership Slump in ACA: The company has experienced significant membership losses in its ACA exchange business, leading to voluntary staff buyouts. This reduces revenue and could signal competitive pressures or pricing issues.
- High Debt-to-Equity Ratio: With a debt-to-equity ratio of 0.94, Centene carries substantial leverage. This increases financial risk, especially if interest rates remain elevated or operating margins fail to improve.
- Potential Overextension After Rally: The stock trades near its 52-week high of $69.36, at 96.6% of that level. The rapid 134% run-up may leave limited upside in the near term, with a possible pullback if momentum stalls.
CNC Technical Analysis
Centene's stock has exhibited a robust recovery over the past year, with a 1-year price change of +134.0%, significantly outperforming the S&P 500's +18.65% gain. The current price of $67.04 sits near the upper end of its 52-week range, at approximately 96.6% of the high of $69.36, indicating strong bullish momentum and investor confidence. This positioning near the highs suggests the stock is in a sustained uptrend, though it may be vulnerable to short-term overextension given the magnitude of the rally.
Beta
1.11
1.11x market volatility
Max Drawdown
-32.7%
Largest decline past year
52-Week Range
$29-$69
Price range past year
Annual Return
+123.9%
Cumulative gain past year
| Period | CNC Return | S&P 500 |
|---|---|---|
| 1m | -1.8% | -0.9% |
| 3m | -1.2% | +5.6% |
| 6m | +86.8% | +15.0% |
| 1y | +123.9% | +18.1% |
| ytd | +54.6% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CNC Fundamental Analysis
Centene's revenue trajectory has been solid, with the most recent quarter (Q1 2026) reporting revenue of $49.94 billion, a 7.13% year-over-year increase from $46.62 billion in Q1 2025. This growth is driven by the Medicaid segment, which contributed $39.21 billion, and the Commercial segment at $9.56 billion, reflecting continued strength in core government programs. However, the company has faced membership declines in its ACA exchange business, leading to cost-cutting initiatives, but the overall revenue trend remains positive, supported by rate adjustments and organic growth.
Quarterly Revenue
$49.9B
2026-03
Revenue YoY Growth
+7.1%
YoY Comparison
Gross Margin
21.9%
Latest Quarter
Free Cash Flow
$6.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CNC Overvalued?
Given that Centene's trailing twelve-month net income is negative (EPS of -$0.33), the price-to-sales (PS) ratio is the most appropriate valuation metric, as it provides a meaningful comparison despite the lack of profitability. The current PS ratio of 0.10x is exceptionally low, while the forward PE of 12.62x suggests the market expects a significant earnings recovery, with analysts projecting EPS of $9.06 for the next fiscal year. This wide gap between trailing losses and forward profitability indicates that investors are pricing in a substantial turnaround, which is supported by the company's strong cash flow generation.
PE
-3.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 3x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-4.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are notable. Centene's trailing twelve-month net income is negative, with an EPS of -$0.33, reflecting recent losses from ACA membership declines and restructuring costs. The debt-to-equity ratio of 0.94 indicates high leverage, which could strain cash flows if interest rates remain elevated. Additionally, the company's operating margin is -3.91%, showing that cost pressures are eroding profitability. While free cash flow is strong at $6.35 billion, the reliance on continued revenue growth to justify the forward PE of 12.62x is a key risk, as any shortfall in earnings recovery could lead to a de-rating.
FAQ
The key risks include: 1) Financial risk from high leverage (debt-to-equity 0.94) and negative operating margin (-3.91%), which could strain cash flows. 2) Competitive and regulatory risks, such as ACA membership losses and potential changes in Medicaid reimbursement rates. 3) Macro risks, including sensitivity to interest rates (beta 1.106) and healthcare policy shifts. 4) Company-specific risks, such as the failure to achieve EPS projections, which would likely lead to a de-rating. The most severe risk is a continued membership slump, which could push the stock down to the 52-week low of $28.24, a -57.9% downside.
The 12-month forecast is bullish, with a base case target of $71.67 (6.9% upside) and a bull case target of $85 (26.8% upside), but a bear case target of $56 (-16.5% downside). The probabilities are 30% bull, 50% base, and 20% bear. The most likely scenario is the base case, which assumes steady revenue growth and EPS recovery. The key assumption is that Centene can stabilize membership and achieve its projected EPS of $9.06. If it does, the stock is likely to appreciate; if not, it could fall.
Based on the price-to-sales ratio of 0.10x and forward PE of 12.62x, CNC appears undervalued relative to its growth prospects and historical averages. The market is pricing in a significant earnings recovery, as evidenced by the wide gap between trailing EPS of -$0.33 and projected EPS of $9.06. If the company achieves these projections, the stock is undervalued; if not, it could be fairly valued or even overvalued. Compared to peers, the valuation is attractive, but the high debt-to-equity ratio of 0.94 adds risk.
CNC is a good buy for investors with a higher risk tolerance, given the potential upside to the analyst high target of $85 (26.8% upside) and the low forward PE of 12.62x. However, the stock carries significant risks, including negative trailing earnings and ACA membership losses. The consensus rating is 'buy' with an average target of $71.67, implying 6.9% upside. For those who believe in the turnaround, the current price offers an attractive entry point, but it is not without downside risk to $56 (-16.5%).
CNC is more suitable for long-term investment, given its turnaround nature and the time required for earnings recovery. The stock has a beta of 1.106, indicating higher volatility than the market, which may deter short-term traders. The company does not pay a dividend, so returns depend on capital appreciation. With a forward PE of 12.62x and projected EPS growth, a minimum holding period of 12-18 months is recommended to allow the turnaround to materialize. Short-term traders might find opportunities in the volatility, but the fundamental thesis is best captured over a longer horizon.
